MLKL and non-alcoholic fatty liver: Therefore, the RIP1 kinase-RIP3 kinase-MLKL-axis may serve as a potential target of small-molecule therapeutics by inhibiting pro-necroptotic pathway in the treatment of NAFL/NASH.